NeurOdys Therapeutics Secures Pre-Seed Funding and to Advance Small Molecule Therapies for Neurodegenerative Diseases
Amsterdam, Netherlands — Rambam AG, a Swiss-based venture studio and a part of the Expert Systems accelerator platform, and NLC Health Ventures, a healthtech venture builder focused on early-stage biotech and digital health companies, announced the pre-seed funding and launch of NeurOdys Therapeutics. Headquartered in Amsterdam, Netherlands. NeurOdys is a cutting-edge biotechnology startup focused on developing transformative treatments for neurodegenerative disorders.
NeurOdys Therapeutics brings together an experienced team of scientists, drug developers, and investors committed to tackling some of the most pressing challenges in neurology. The company is focused on discovering and advancing novel small molecules designed to modify disease progression and improve patient outcomes in conditions such as Alzheimer’s, Parkinson’s, and other neurodegenerative disorders.
“Neurodegenerative diseases are among the most pressing and complex challenges in modern medicine,” said Dr. Vasily Kazey, CEO of NeurOdys Therapeutics. “With the support of Rambam AG and NLC Health Ventures we are poised to make meaningful advances toward disease-modifying therapies.”
NeurOdys will focus on the rapid identification and development of potential therapeutics using cutting-edge computational modeling and discovery technologies. This approach will be supported by the drug development expertise of Expert Systems Accelerator, a vertically integrated AI-powered drug discovery platform.
About Rambam AG
Rambam AG is a Swiss-based venture studio and accelerator platform for breakthrough drug discovery and development. Rambam diversified portfolio of companies and programs is supported by a core group of seasoned industrial experts, key opinion leaders and dedicated functional experts from Switzerland, Netherlands, Portugal, Germany and the US.
About NLC Health Ventures
Based out of Amsterdam, NLC Health Ventures is the most active health technology investor in Europe and the world’s largest healthtech venture builder. NLC finds, builds, and scales transformative health innovations to provide more patients with quality care. NLC is ‘BCorp,’ its funds comply with SFDR9 guidelines, and they contribute to ESG 3, 9, and 17. With more than 100 startups, 4 funds, and activity in 16 countries, they bring impactful innovations to patients on a large scale. The NLC Health Impact Fund is NLC’s newest and largest fund to date, investing in NLC’s startups. The fund deploys capital for ventures at various stages, providing both initial and follow-up funding.
Media contact:
Vasily Kazey
CEO
vkazey@neurodysther.com